MTOR and tuberous sclerosis: Fourth, the KD can inhibit the mTOR pathway, which (1) can affect epileptogenesis (26, 32) and (2) can reduce the hyperactivation that has been implicated in patients with tuberous sclerosis complex (TSC), cortical developmental malformations, and DRE (33).